C. Higgs

发表

Does an HIV clinical trial information booklet improve patient knowledge and understanding of HIV clinical trials?

N. Ives, M. Troop, A. Waters, 2001, HIV medicine.

Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow‐up in Patients Infected with Human Immunodeficiency Virus

M. Youle, G. Moyle, W. Prince, 1998, Journal of clinical pharmacology.

Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir

D. Fuchs, A. Winston, A. Boasso, 2018, Journal of NeuroVirology.

A Compartmental Pharmacokinetic Evaluation of Long‐Acting Rilpivirine in HIV‐Negative Volunteers for Pre‐Exposure Prophylaxis

B. Gazzard, B. Herold, M. Boffito, 2014, Clinical pharmacology and therapeutics.

Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate

M. Boffito, A. Mathias, B. Kearney, 2005, Antimicrobial Agents and Chemotherapy.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients

B. Gazzard, M. Boffito, D. Back, 2004, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen

B. Gazzard, M. Boffito, D. Back, 2003, Antiviral therapy.

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

B. Gazzard, S. Khoo, N. Liptrott, 2011, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects.

D. Hawkins, M. Youle, A. Lant, 1999, AIDS research and human retroviruses.

Pharmacokinetics and Absolute Bioavailability of Oral Foscarnet in Human Immunodeficiency Virus-Seropositive Patients

B. Gazzard, M. Youle, S. Martin-Munley, 1998, Antimicrobial Agents and Chemotherapy.

Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV.

D. Hawkins, G. Moyle, N. Buss, 2002, British journal of clinical pharmacology.

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

A. Winston, L. Waters, N. Perry, 2011, AIDS.

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge

S. Khoo, M. Boffito, G. Moyle, 2017, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2011, Antimicrobial Agents and Chemotherapy.

Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.

B. Walker, E. Karita, O. Anzala, 2010, The Journal of infectious diseases.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation

S. Khoo, M. Boffito, D. Back, 2015, Antimicrobial Agents and Chemotherapy.

Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects

M. Boffito, G. Moyle, P. Hay, 2009, Antimicrobial Agents and Chemotherapy.

M. Boffito, G. Moyle, P. Hay, 2009 .

Immunodeficiency Virus-Infected Subjects 300 Milligrams Twice Daily in Human Abacavir at 600 Milligrams Once Daily and Triphosphate following Administration of in Plasma and Intracellular Carbovir Steady-State Pharmacokinetics of Abacavir

M. Boffito, G. Moyle, P. Hay, 2009 .

Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials.

Frances Gotch, Peter Kelleher, Ambreen Ashraf, 2011, Journal of immunological methods.

Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir

D. Fuchs, A. Winston, A. Boasso, 2018, Journal of NeuroVirology.

An Open-Label, Randomized Comparative Pilot Study of a Single-Class Quadruple Therapy Regimen versus a 2–Class Triple Therapy Regimen for Individuals Initiating Antiretroviral Therapy

Martin Fisher, Sundhiya Mandalia, B. Gazzard, 2006, Antiviral therapy.

Diabetes in An Hiv Population: A Hidden Epidemic?

Feher, Y. Samarasinghe, C. Higgs, 2002 .

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV

A. Winston, C. Sabin, M. Youle, 2019, HIV medicine.

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals

S. Khoo, M. Boffito, D. Back, 2018, HIV clinical trials.

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.

S. Khoo, M. Boffito, G. Moyle, 2017, The Journal of antimicrobial chemotherapy.